The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case-control study in Asia

Vaccine

Volumn 30, Issue 28, 2012, Pages 4292-4298

  Uno, Yota ^a,b   Uchiyama, Tokio ^b,c   Kurosawa, Michiko ^d   Aleksic, Branko ^a   Ozaki, Norio ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yokohama Psycho Developmental Clinic   (Japan)

^c FUKUSHIMA UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autism spectrum disorder; Case control studies; Measles mumps rubella Vaccine; Medical record; Risk factors; Vaccination

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE;

ADULT; ARTICLE; AUTISM; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VACCINATION;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; JAPAN; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; RUBELLA; VACCINATION;

EID: 84861656165     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.093     Document Type: Article

References (50)

1. Lotter V. Childhood autism in Africa. J Child Psychol Psychiatry 1978, 19:231-244.
2. Wing L. Autistic spectrum disorders. BMJ 1996, 312:327-328.
3. Wing L. The autistic spectrum. Lancet 1997, 350:1761-1766.
4. Baird G., Simonoff E., Pickles A., Chandler S., Loucas T., Meldrum D., et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006, 368:210-215.
5. Brugha T.S., McManus S., Bankart J., Scott F., Purdon S., Smith J., et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry 2011, 68:459-465.
6. Kim Y.S., Leventhal B.L., Koh Y.J., Fombonne E., Laska E., Lim E.C., et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011.
7. Levy S.E., Mandell D.S., Schultz R.T. Autism. Lancet 2009, 374:1627-1638.
8. Hallmayer J., Cleveland S., Torres A., Phillips J., Cohen B., Torigoe T., et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011, 68:1095-1102.
9. Lichtenstein P., Carlstrom E., Rastam M., Gillberg C., Anckarsater H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010, 167:1357-1363.
10. Wakefield A.J., Murch S.H., Anthony A., Linnell J., Casson D.M., Malik M., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998, 351:637-641.
11. Lancet T.E.O.T. Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010, 375:445.
12. Kawashima H., Mori T., Kashiwagi Y., Takekuma K., Hoshika A., Wakefield A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci 2000, 45:723-729.
13. Uhlmann V., Martin C.M., Sheils O., Pilkington L., Silva I., Killalea A., et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002, 55:84-90.
14. Delong G. A positive association found between autism prevalence and childhood vaccination uptake across the U.S. population. J Toxicol Environ Health A 2011, 74:903-916.
15. Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics 1999, 104:568-569.
16. Bernard S., Enayati A., Redwood L., Roger H., Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001, 56:462-471.
17. Offit P.A. Vaccines and autism revisited-the Hannah Poling case. N Engl J Med 2008, 358:2089-2091.
18. Farrington C.P., Miller E., Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001, 19:3632-3635.
19. del Kaye J.A., Mar Melero-Montes M., Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001, 322:460-463.
20. Dales L., Hammer S.J., Smith N.J. Time trends in autism and in MMR immunization coverage in California. JAMA 2001, 285:1183-1185.
21. Fombonne E., Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001, 108:E58.
22. Makela A., Nuorti J.P., Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002, 110:957-963.
23. Taylor B., Lingam R., Simmons A., Stowe J., Miller E., Andrews N. Autism and MMR vaccination in North London; no causal relationship. Mol Psychiatry 2002, 7(Suppl. 2):S7-S8.
24. Madsen K.M., Hviid A., Vestergaard M., Schendel D., Wohlfahrt J., Thorsen P., et al. A population based study of MMR vaccination and autism. New Engl J 2002, 347:1477-1482.
25. Chen W., Landau S., Sham P., Fombonne E. No evidence for links between autism, MMR and measles virus. Psychol Med 2004, 34:543-553.
26. Richler J., Luyster R., Risi S., Hsu W.L., Dawson G., Bernier R., et al. Is there a 'regressive phenotype' of autism spectrum disorder associated with the measles-mumps-rubella vaccine? A CPEA Study. J Autism Dev Disord 2006, 36:299-316.
27. Taylor B., Miller E., Farrington C.P., Petropoulos M.C., Favot-Mayaud I., Li J., et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999, 353:2026-2029.
28. Fombonne E., Zakarian R., Bennett A., Meng L., McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006, 118:e139-e150.
29. Honda H., Shimizu Y., Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry 2005, 46:572-579.
30. Uchiyama T., Kurosawa M., Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord 2007, 37:210-217.
31. DeStefano F., Bhasin T.K., Thompson W.W., Yeargin-Allsopp M., Boyle C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 2004, 113:259-266.
32. Smeeth L., Cook C., Fombonne E., Heavey L., Rodrigues L.C., Smith P.G., et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004, 364:963-969.
33. DeWilde S., Carey I.M., Richards N., Hilton S.R., Cook D.G. Do children who become autistic consult more often after MMR vaccination. Br J Gen Pract 2001, 51:226-227.
34. Stephen D., Sugarman S.D. Cases in vaccine court-legal battles over vaccines and autism. N Engl J Med 2007, 357:1275-1277.
35. Casiday R., Cresswell T., Wilson D., Panter-Brick C. A survey of UK parental attitudes to the MMR vaccine and trust in medical authority. Vaccine 2006, 24:177-184.
36. Cassell J.A., Leach M., Poltorak M.S., Mercer C.H., Iversen A., Fairhead J.R. Is the cultural context of MMR rejection a key to an effective public health discourse. Public Health 2006, 120:783-794.
37. Hilton S., Hunt K., Petticrew M. MMR: marginalised, misrepresented and rejected? Autism: a focus group study. Arch Dis Child 2007, 92:322-327.
38. Haga H., Yamada R., Ohnishi Y., Nakamura Y., Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 2002, 47:605-610.
39. Kunugi H., Nanko S., Takei N., Saito K., Murray R.M., Hirose T. Perinatal complications and schizophrenia. Data from the Maternal and Child Health Handbook in Japan. J Nerv Ment Dis 1996, 184:542-546.
40. Ohara K., Tanabu S., Yoshida K., Sato Y., Shibuya H. Obstetric complications in siblings of Japanese schizophrenics: data from the Maternal and Child Health Handbook. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:617-620.
41. Wing L., Leekam S.R., Libby S.J., Gould J., Larcombe M. The diagnostic interview for social and communication disorders: background, inter-rater reliability and clinical use. J Child Psychol Psychiatry 2002, 43:307-325.
42. Leekam S.R., Libby S.J., Wing L., Gould J., Taylor C. The diagnostic interview for social and communication disorders: algorithms for ICD-10 childhood autism and Wing and Gould autistic spectrum disorder. J Child Psychol Psychiatry 2002, 43:327-342.
43. Nygren G., Hagberg B., Billstedt E., Skoglund A., Gillberg C., Johansson M. The Swedish version of the Diagnostic Interview for Social and Communication Disorders (DISCO-10). Psychometric properties. J Autism Dev Disord 2009, 39:730-741.
44. Sugiura A., Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991, 10:209-213.
45. Eaton W.W., Mortensen P.B., Thomsen P.H., Frydenberg M. Obstetric complications and risk for severe psychopathology in childhood. J Autism Dev Disord 2001, 31:279-285.
46. Hultman C.M., Sparen P., Cnattingius S. Perinatal risk factors for infantile autism. Epidemiology 2002, 13:417-423.
47. Glasson E.J., Bower C., Petterson B., de Klerk N., Chaney G., Hallmayer J.F. Perinatal factors and the development of autism: a population study. Arch Gen Psychiatry 2004, 61:618-627.
48. Larsson H.J., Eaton W.W., Madsen K.M., Vestergaard M., Olesen A.V., Agerbo E., et al. Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am J Epidemiol 2005, 161:916-925. discussion 26-8.
49. Gardener H., Spiegelman D., Buka S.L. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychiatry 2009, 195:7-14.
50. Thompson W.W., Price C., Goodson B., Shay D.K., Benson P., Hinrichsen V.L., et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007, 357:1281-1292.